evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 40%GRADE not reported 0 · 0%Very low 2 · 40%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Recurrence · patients with non‐muscle invasive bladder cancer

It is very uncertain whether intravesically administered BCG combined with IFN‐α changes recurrence compared with intravesically administered BCG alone (very low certainty).

1 finding from 1 review

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Disease progression · patients with non‐muscle invasive bladder cancer

Intravesically administered BCG combined with IFN‐α showed no clear difference in progression compared with intravesically administered BCG alone (low certainty).

1 finding from 1 review

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Discontinuation of therapy due to adverse events ‐ not measured · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Disease‐specific mortality ‐ not reported · patients with non‐muscle invasive bladder cancer

It is very uncertain whether intravesically administered BCG combined with IFN‐α changes disease‐specific mortality compared with intravesically administered BCG alone (very low certainty).

1 finding from 1 review

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Disease‐specific quality of life ‐ not reported · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review